Behavioral and Neurochemical Effects of 5-{4-[4-(5-Cyano-3-indolyl)-butyl)-butyl]-1-piperazinyl}-benzofuran-2-carboxamide (EMD 68843): A Combined Selective Inhibitor of Serotonin Reuptake and 5-Hydroxytryptamine1A Receptor Partial Agonist

  title={Behavioral and Neurochemical Effects of 5-\{4-[4-(5-Cyano-3-indolyl)-butyl)-butyl]-1-piperazinyl\}-benzofuran-2-carboxamide (EMD 68843): A Combined Selective Inhibitor of Serotonin Reuptake and 5-Hydroxytryptamine1A Receptor Partial Agonist},
  author={Michelle E. Page and John F. Cryan and A. O. Sullivan and Ashutosh Dalvi and Berangere Saucy and David R Manning and Irwin Lucki},
  journal={Journal of Pharmacology and Experimental Therapeutics},
  pages={1220 - 1227}
  • M. Page, J. Cryan, I. Lucki
  • Published 1 September 2002
  • Biology
  • Journal of Pharmacology and Experimental Therapeutics
5-{4-[4-(5-Cyano-3-indolyl)-butyl)-butyl]-1-piperazinyl}-benzofuran-2-carboxamide (EMD 68843; vilazodone) is a novel compound with combined high affinity and selectivity for the 5-hydroxytryptamine (5-HT) transporter and 5-HT1A receptors. EMD 68843 was tested as a prototype compound, which benefits from dual pharmacological effects that could increase extracellular 5-HT to levels higher than those produced by conventional selective serotonin reuptake inhibitors (SSRIs). In Sf9 cells, EMD 68843… 

Figures and Tables from this paper

Novel 4-aryl-pyrido[1,2-c]pyrimidines with dual SSRI and 5-HT(1A) activity. Part 5.
Mechanism of action of the bimodal antidepressant vilazodone: evidence for serotonin1A-receptor-mediated auto-augmentation of extracellular serotonin output
In spite of high intrinsic 5-HT1A activity in reserpinized rats, the net effect of vilazodone at release-regulating 5- HT1A autoreceptors must be inhibitory, leading to markedly increased 5-ht output.
Chapter 6 Association of 5-HT 1 A Receptors with Affective Disorders
The purpose of this chapter is to analyze and discuss the current information about 5-HT 1A -R-mediated signaling cascades, the intracellular signaling of 5- HT 1A-R, in addition to their expression and pharmacology that are important to treatment of affective disorders symptoms.


WAY100135: a novel, selective antagonist at presynaptic and postsynaptic 5-HT1A receptors.
Antidepressant-like behavioral effects in 5-hydroxytryptamine(1A) and 5-hydroxytryptamine(1B) receptor mutant mice.
The results suggest that 5-HT(1A) and 5- HT(1B) receptors have different roles in the modulation of the response to antidepressant drugs in the TST, suggesting mediation by enhanced catecholamine function.
Agonist-independent activation of Gz by the 5-hydroxytryptamine1A receptor co-expressed in Spodoptera frugiperda cells. Distinguishing inverse agonists from neutral antagonists.
The human 5-hydroxytryptamine1A receptor, when expressed in Spodoptera frugiperda (Sf9) cells, facilitates the binding of [35S]GTPgammaS to a co-expressed GTP-binding regulatory protein, Gz, consistent with constitutive activity, using G protein activation as an index of receptor activity.
Genetic regulation of extracellular serotonin by 5-hydroxytryptamine(1A) and 5-hydroxytryptamine(1B) autoreceptors in different brain regions of the mouse.
Results indicate common topographical regulation of 5-HT release in different brain regions by genetic mutation and pharmacological challenges and play a larger role in regulating 5- HT release in the striatum and possibly other brain regions innervated by the dorsal raphe nucleus.
Partial 5-HT1A receptor agonist properties of (–)pindolol in combination with citalopram on serotonergic dorsal raphe cell firing in vivo
The present findings support the previous notion that (–)pindolol possesses prominent agonistic activity at somatodendritic 5-HT1A autoreceptors, but also indicate that it may possess a weak antagonistic action at these receptors.
Effects of (−)‐tertatolol, (−)‐penbutolol and (±)‐pindolol in combination with paroxetine on presynaptic 5‐HT function: an in vivo microdialysis and electrophysiological study
The data suggest that (-)‐tertatolol and (−)‐penbutolol are superior to (±)‐pindolol in terms of enhancing the effect of an SSRI on extracellular 5‐HT in the frontal cortex and both are worthy of investigation for use as adjuncts to SSRIs in the treatment of major depression.